BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given a consensus recommendation of “Moderate Buy” by the nineteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $127.8125.

BNTX has been the subject of several recent analyst reports. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Morgan Stanley reduced their target price on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $117.00 to $135.00 in a research report on Wednesday, May 27th. Finally, Wells Fargo & Company lowered their price target on BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech announced that it will present new data from its late-stage lung-cancer program at the 2026 World Conference on Lung Cancer. The company plans to highlight its investigational combination of pumitamig and elfetabart drozuntecan, along with progress across its broader oncology pipeline. The upcoming data provide a potential catalyst for the company’s longer-term growth beyond COVID-19 products. BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Combination
• Positive Sentiment: BioNTech initially benefited from investor enthusiasm following Moderna’s cancer-vaccine breakthrough, as traders viewed the results as validation for mRNA-based oncology and potentially supportive of BioNTech’s own cancer pipeline. Unusually heavy call-option buying—8,783 contracts, reportedly 478% above average—also indicated strong speculative interest. Why Is BioNTech Stock Surging on Wednesday?
• Neutral Sentiment: Analyst commentary is focused on BioNTech’s oncology strategy and pipeline, but the available reports do not identify a major new change to earnings estimates or price targets. Investors are therefore likely to focus on future clinical data rather than near-term financial results. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Moderna’s shares reversed sharply after their dramatic prior-session gain, dragging BioNTech and other mRNA-related stocks lower. The move suggests investors are taking profits across the sector rather than assigning immediate value to BioNTech based solely on Moderna’s trial results. Leerink also cautioned that BioNTech’s rally could fade, reinforcing the risk of a short-term pullback. BioNTech’s Rally on Moderna Trial Win Likely to Fade

Institutional Trading of BioNTech

Several large investors have recently bought and sold shares of BNTX. Royal Bank of Canada increased its stake in shares of BioNTech by 95.9% during the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock worth $653,000 after purchasing an additional 3,514 shares in the last quarter. NewEdge Advisors LLC purchased a new position in BioNTech in the first quarter valued at approximately $167,000. Russell Investments Group Ltd. raised its stake in shares of BioNTech by 368,800.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after acquiring an additional 11,064 shares during the period. Natixis acquired a new position in shares of BioNTech during the second quarter worth about $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in BioNTech by 2.9% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock worth $52,416,000 after acquiring an additional 13,788 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX stock opened at $110.89 on Friday. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $92.91 and its two-hundred day moving average is $95.64. The company has a market capitalization of $28.04 billion, a P/E ratio of -14.16 and a beta of 1.27.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company’s quarterly revenue was down 59.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.60) earnings per share. Analysts expect that BioNTech will post -6.33 EPS for the current fiscal year.

BioNTech declared that its board has initiated a stock buyback program on Thursday, May 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its stock is undervalued.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.